Coverage
-
February 20, 2019
The Federal Trade Commission's settlement this week with Teva Pharmaceuticals further winnows the types of deals the company can sign with would-be competitors and illuminates the agency's evolving approach to cases in which drug companies are accused of colluding to delay competition.
4 other articles on this case.
View all »